M344
Based on 2 publication(s) in Google Scholar
M344 (D 237) is an inhibitor of histone deacetylase (IC50=100 nM) and an inducer of terminal cell fifferentiation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.30%
- CAS No.: 251456-60-7
- Formule: C16H25N3O3
- Masse moléculaire:307.39
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Osteogenesis Compound Library
HY-L131
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) M344
More
Activité biologique
|
HDAC 100 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | IC50 |
2.3 μM
Compound: 23
|
Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type.
Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type.
|
[PMID: 11831887] |
| A549 | IC50 |
0.8 μM
Compound: 23
|
Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type.
Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type.
|
[PMID: 11831887] |
| HCT-116 | IC50 |
0.2 μM
Compound: 23
|
Concentration required to inhibit the colon HCT116 cell growth by 50%,P53 status of cell line used was wild-type.
Concentration required to inhibit the colon HCT116 cell growth by 50%,P53 status of cell line used was wild-type.
|
[PMID: 11831887] |
| HCT-116 | IC50 |
0.21 μM
Compound: 23
|
Concentration required to inhibit the HCT116 cell growth by 50%.
Concentration required to inhibit the HCT116 cell growth by 50%.
|
[PMID: 11831887] |
| LS174T | IC50 |
1.5 μM
Compound: 23
|
Concentration required to inhibit the colon LS 174T cell growth by 50%,P53 status of cell line used was mutant-type.
Concentration required to inhibit the colon LS 174T cell growth by 50%,P53 status of cell line used was mutant-type.
|
[PMID: 11831887] |
| NCI-H1299 | IC50 |
3.9 μM
Compound: 23
|
Concentration required to inhibit the lung H1299 cell growth by 50%,P53 status of cell line used was wild-type.
Concentration required to inhibit the lung H1299 cell growth by 50%,P53 status of cell line used was wild-type.
|
[PMID: 11831887] |
| SW-620 | IC50 |
0.7 μM
Compound: 23
|
Concentration required to inhibit the colon SW 620 cell growth by 50%,P53 status of cell line used was mutant-type.
Concentration required to inhibit the colon SW 620 cell growth by 50%,P53 status of cell line used was mutant-type.
|
[PMID: 11831887] |
| T-24 | IC50 |
3.8 μM
Compound: 23
|
Concentration required to inhibit the bladder T24 cell growth by 50%,P53 status of cell line used was wild-type.
Concentration required to inhibit the bladder T24 cell growth by 50%,P53 status of cell line used was wild-type.
|
[PMID: 11831887] |
M344 is a potential histone deacetylase (HDAC) inhibitor. With increasing concentrations of M344, there is a dose dependant decrease in BRCA1 mRNA and treatment with both 1 and 5 μM concentrations of M344 resulting in a significant decrease in BRCA1 expression in all cell lines examined. M344 in combination with Cisplatin leads to a decrease in BRCA1 mRNA expression as compared to Cisplatin treatment alone in all cell lines with the exception of A2780s, which is recognized as having potent cytotoxicity to Cisplatin. In the MCF7 cell line, BRCA1 is down regulated at physiological doses of M344 (0.5 μM and 1 μM) but M344 does not have the same inhibitory effect on BRCA1 at the 5.0 μM dose. Co-treatment with Cisplatin and increasing concentrations of M344 reduces BRCA1 protein levels in all breast and ovarian cell lines examined[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 251456-60-7
-
Appearance Solid
-
Masse moléculaire 307.39
-
Formule C16H25N3O3
-
Color White to off-white
-
SMILES
O=C(NCCCCCCC(NO)=O)C1=CC=C(N(C)C)C=C1
-
Synonyms
D 237; MS 344
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Technol Cancer Res Treat
Role of lncRNA AGAP2-AS1 in Breast Cancer Cell Resistance to Apoptosis by the Regulation of MTA1 Promoter Activity. [Abstract]Jan-Dec 2022;21:15330338221085361. PMID: 35369814
Solvant et solubilité
DMSO : ≥ 100 mg/mL (325.32 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.13 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (32.53 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
The A2780s and A2780cp cell lines, the T-47D and OVCAR-4 cell lines. and the MCF7 and HCC1937cell lines, are maintained in Dulbecco's-MEM supplemented with 10% fetal bovine serum and 100 μg/mL penicillin-streptomycin. Unless otherwise described, cells are treated for 24 hrs with 2 μg/mL Cisplatin alone, and in combination with the HDAC inhibitor M344 at concentrations of 0.5, 1.0, or 5.0 μM. Phase contrast images are collected using the 10× objective of an Eclipse TE2000-U. Cell viability is measured by the MTT rapid colorimetric assay. Approximately 4,500 cells are seeded into each well of a 96-well flat bottom plate. The cells are incubated overnight to allow for cell attachment. Cells are then treated with Cisplatin in concentrations of 0-8 μg/mL alone or in combination with 1 μM of the HDAC inhibitor, M344. Forty eight hours following treatment, 42 μL of a 5 mg/mL MTT substrate solution in phosphate buffered saline (PBS) is added and incubated for up to 4 hrs at 37°C. The resulting violet formazan precipitate is solubilized by the addition of 82 μL of a 0.01 M HCl/10% SDS solution and plates are incubated overnight at 37°C. The plates are then analyzed on an MRX Microplate Reader at 570 nm to determine the optical density of the samples[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Jung M1, et al. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79. [Content Brief]
[2]. Weberpals JI, et al. The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells. Cancer Cell Int. 2011 Aug 19;11(1):29. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2532 mL | 16.2660 mL | 32.5320 mL | 81.3299 mL |
| 5 mM | 0.6506 mL | 3.2532 mL | 6.5064 mL | 16.2660 mL | |
| 10 mM | 0.3253 mL | 1.6266 mL | 3.2532 mL | 8.1330 mL | |
| 15 mM | 0.2169 mL | 1.0844 mL | 2.1688 mL | 5.4220 mL | |
| 20 mM | 0.1627 mL | 0.8133 mL | 1.6266 mL | 4.0665 mL | |
| 25 mM | 0.1301 mL | 0.6506 mL | 1.3013 mL | 3.2532 mL | |
| 30 mM | 0.1084 mL | 0.5422 mL | 1.0844 mL | 2.7110 mL | |
| 40 mM | 0.0813 mL | 0.4066 mL | 0.8133 mL | 2.0332 mL | |
| 50 mM | 0.0651 mL | 0.3253 mL | 0.6506 mL | 1.6266 mL | |
| 60 mM | 0.0542 mL | 0.2711 mL | 0.5422 mL | 1.3555 mL | |
| 80 mM | 0.0407 mL | 0.2033 mL | 0.4066 mL | 1.0166 mL | |
| 100 mM | 0.0325 mL | 0.1627 mL | 0.3253 mL | 0.8133 mL |
M344 Related Classifications
HY-13506 Related Classifications
Powered by Bioz